Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Neutrophil Extracellular Traps (NETs) and Covid-19: A new frontiers for therapeutic modality

Hayder M. Al-Kuraishy a, Ali I. Al-Gareeb a, Hany Akeel Al-hussaniy b, Nasser A. Hadi Al-Harcan c, Athanasios Alexiou d, e, f, Gaber El-Saber Batiba f, * 

a Department of Clinical Pharmacology and Medicine, College of Medicine, Al-Mustansiriyah University, Baghdad, Iraq 
b Department of Pharmacology, College of Anesthetic, Al-Nikhaba University-Baghdad, Iraq 
c Department of Clinical Pharmacology and Medicine, College of Medicine, Al-Rasheed University College, Baghdad, Iraq 
d Department of Science and Engineering, Novel Global Community Educational Foundation, Hebersham, Australia 
e AFNP Med Austria, Wien, Austria 
f Department of Pharmacology and Therapeutics, Faculty of Veterinary Medicine, Damanhour University, Damanhour 22511, Al Beheira, Egypt

ARTICLE INFO

Keywords: 
Covid-19 Neutrophil extracellular traps Cytokine storm Immuno-thrombosis Acute lung injury Acute respiratory distress syndrome

ABSTRACT

Coronavirus disease 2019 (Covid-19) is a worldwide infectious disease caused by severe acute respiratory coronavirus 2 (SARS-CoV-2). In severe SARS-CoV-2 infection, there is severe inflammatory reactions due to neutrophil recruitments and infiltration in the different organs with the formation of neutrophil extracellular traps (NETs), which involved various complications of SARS-CoV-2 infection. Therefore, the objective of the present review was to explore the potential role of NETs in the pathogenesis of SARS-CoV-2 infection and to identify the targeting drugs against NETs in Covid-19 patients. Different enzyme types are involved in the formation of NETs, such as neutrophil elastase (NE), which degrades nuclear protein and release histones, peptidyl arginine deiminase type 4 (PADA4), which releases chromosomal DNA and gasdermin D, which creates pores in the NTs cell membrane that facilitating expulsion of NT contents. Despite of the beneficial effects of NETs in controlling of invading pathogens, sustained formations of NETs during respiratory viral infections are associated with collateral tissue injury. Excessive development of NETs in SARS-CoV-2 infection is linked with the development of acute lung injury (ALI) and acute respiratory distress syndrome (ARDS) due to the creation of the NETs-IL-1β loop. Also, aberrant NTs activation alone or through NETs formation may augment SARS-CoV-2-induced cytokine storm (CS) and macrophage activation syndrome (MAS) in patients with severe Covid-19. Furthermore, NETs formation in SARS-CoV-2 infection is associated with immuno-thrombosis and the development of ALI/ARDS. Therefore, anti-NETs therapy of natural or synthetic sources may mitigate SARS-CoV-2 infection-induced exaggerated immune response, hyperinflammation, immuno-thrombosis, and other complications.

1. Introduction

Covid-19 is a global pandemic infectious disease caused by severe acute respiratory syndrome coronavirus (SARS-CoV-2), affecting various organ types, principally the respiratory system, and presenting with pulmonary and extra-pulmonary manifestations [1]. Acute lung injury (ALI) and acute respiratory distress syndrome (ARDS) are the most severe pulmonary manifestations. However, extra-pulmonary manifestation like acute cardiac injury, neurological disorders, pancreatic injury, and acute kidney injury (AKI) are evident [1]. This systemic effect of Covid-19 is linked with the wide distribution of angiotensin-converting enzyme 2 (ACE2), which is an entry point for SARS-CoV-2 [2]. It has been shown that ACE2 is highly expressed in various tissues, including lung alveolar cells type II, proximal renal tubules, immune cells, and intestines [3]. Furthermore, the binding of SARS-CoV-2 to the ACE2 is linked with down-regulation of ACE2, intensification in the level of harmful angiotensin II (AngII), reduction of protective Ang1-7, Ang1-9, and release of pro-inflammatory cytokines [4].

The World Health Organization (WHO) declaration that this disease is a pandemic, and till late March 2021, the total established cases are 123,012,799, with 2,715,472 deaths. In this universal dilemma, diverse efforts and advancing research are built-up to find effective agents.
against SARS-CoV-2 from recent or old approved drugs as a repurposing drug strategy [5]. Older age groups and comorbidities such as hypertension, diabetes mellitus, and chronic kidney disease are linked with Covid-19 severity [6]. Regarding the clinical presentations of Covid-19 patients, most of them are asymptomatic or have mild symptoms; however, 10%-20% of them developed and experienced severe to critical clinical presentations with progression of ALI due to the development of hypercytokinemia and cytokine storm (CS) [7].

Generally, in severe SARS-CoV-2 infection, there are strong inflammatory reactions because of neutrophil recruitments and infiltration in the different organs with the formation of neutrophil extracellular traps (NETs), which involved with various severe consequences of SARS-CoV-2 infection such as ALI, ARDS, CS, pulmonary thrombosis and multi-organ damage (MOD) [8].

Thus, the present study aimed to explore the possible role of NETs in the SARS-CoV-2 infection and to identify the targeting drugs against NETs in Covid-19.

2. Neutrophil extracellular traps and respiratory viral infections

Neutrophils (NTs) represent approximately 60% of blood leukocytes and are the primary immune cells and first-line guard alongside entering pathogens [206]. Typically, NTs are formed in humans each day; they have a short half-life and high metabolic functions [9]. It has been reported that NTs are often also participating against viral infections; thereby, a large number of NTs are accumulated in the pulmonary circulation in a steady state due to frequent interactions with invading respiratory viruses [10]. However, exaggerated immune function and activity of NTs are associated with the development of ALI due to the generation of free radicals, reactive oxygen species, and discharge of harmful proteolytic enzymes [11].

In respiratory viral infections, NTs and other phagocytic cells leave circulation and resident infected pulmonary sites in response to the inflammatory cytokines, chemokines, interferon (IFN), and pathogen-associated molecular patterns (PAMPs) [12]. Likewise, NTs are contemporary in the respiratory tract and show an important role in respiratory immunity against influenza A and avian influenza viruses. In addition, higher NTs in the lower respiratory tract during acute influenza A infection are linked with the infection severity [13].

Furthermore, NTs illustrate a more vigorous and dynamic defense against respiratory viral infection and other type of infections in cooperation with platelets in forming NETs that protect from viral infections [14] [Fig. 1].

Besides, NETosis is defined as the formation of NETs during NTs programmed cell death [14]. In addition, the formation of NETs may also develop without damage to the NT cell membrane with preserving normal phagocytic and chemotactic functions [15,207]. Both NETs and NETosis control viral severity; Hiroki et al [16] illustrated that NETosis is a natural process that prevents acute Chikungunya viral infection by reducing systemic viral load.

NETs are net-like structures consisting of neutrophil granule proteins, DNA, and chromatin expelled from the NTs to ensnare invading pathogens [208]. Different enzyme types are involved in the formation of NETs, such as neutrophil elastase (NE), which degrades nuclear protein and release histones, peptidyl arginine deiminase type 4 (PADA4) that releases chromosomal DNA and gadermin D that creates damage in the NTs cell membrane that facilitating expulsion of NT contents [17].

Despite the beneficial effects of NETs in controlling invading pathogens, sustained formations of NETs during respiratory viral infections are associated with a collateral tissue injury [18]. In addition, various studies showed that higher and excessive formations of NETs might activate inflammatory reactions that induce systemic coagulopathy, localized micro-thrombosis, and MOD [17] [Fig. 2].

The interaction between the viruses and the NTs in the induction of NETs and NETosis is ill-defined; however, it may be direct or indirect interactions [19]. Different types of viruses at a low level can stimulate NTs in vitro to produce NETs [19]. The virus can enter the NT and induce NETs or NETosis through specific surface or endosomal pattern recognition receptors (PRRs) of NTs; for example, the NTs sense human immune deficiency virus (HIV) via Toll-like receptors (TLR) type 7 and 8, and consequently undergo NETosis [20]. Also, through its fusion protein, respiratory syncytial virus (RSV) can interact with the NT TLR4 for induction of NETs and with β2-integrins for induction of NETosis [21]. On the other hand, the viruses can induce NET formations via the PRRs-independent pathway; the inflammatory chemokines and cytokines such as INF and IL-8 are engaged with NET generation [22,209]. Also, activated platelets during viral infections may play a role in inducing NET formations [23].

In this regard, some NTs are susceptible and primed for NET formations, either NETs or NETosis; however, most NTs are switched for phagocytic action rather than apoptotic pathway depending on the antiviral effector program of the NTs [24]. Thus, some proportion of the NTs is subjected to NETosis while other proportion forms NETs. The structure and function of NETs induced during viral infections are substantially different from that induced by bacterial infections and metabolic diseases [24,210,211].
NETs formation during acute viral infections might be valuable in restricting viral spread; chromatins of NETs bind and restrain viral particles through electrostatic attractions since the histones are positive charge molecules that can bind the negative charge viral envelopes proteins [25]. Also, NETs histones can induce aggregation of influenza particles, inhibit HIV transcription, prevent adsorption of noroviruses [25].

Further, NETs also contain different antiviral molecules such as cathelicidins and myeloperoxidase, which inactivate a wide range of enveloped and non-enveloped viruses [26]. In addition, NETs components may improve antiviral immunity. For example, Xu et al. [27] exhibited that high mobility group box-1 proteins and histones may trigger the release of pro-inflammatory cytokines and chemokines from other immune cells; however, this process is limited since high NETs

Fig. 2. Generation of Neutrophil extracellular traps (adopted from Papayannopoulos 2018 [17]).

Fig. 3. Neutrophil extracellular traps and invading pathogens (adopted from Cortjens et al., 2017 [28]).
aggregates, degrade and metabolize these chemokines and cytokines [28]. Alongside, NETs also can trigger innate immunity through activation release of IFN from dendritic cells and adaptive immunity via activation of T lymphocytes [28] (Fig. 3).

Into the bargain, the virus can evade the NETs through induction the release of IL-10 from dendritic cells, which inhibit NTs TLR-mediated activation. For example, the Dengue virus inhibits NETs formation via reduction of glucose uptake, and the Herpes virus has DNase activity, which degrades the formed NETs [29].

These observations demonstrated the potential role of NETs formation in limiting of various viral infections.

3. Covid-19 and neutrophil extracellular traps

In patients with Covid-19, the NTs number is increased with significant lymphopenia, so neutrophil-lymphocyte ratio (NLR) is augmented [212]. High NLR is correlated with underlying inflammatory reactions and is an independent risk factor for Covid-19 severity [30]. In SARS-CoV-2 infection, different chemokines and cytokines that act as NTs attractants are elevated primarily in patients with severe Covid-19, suggesting the possible role of the NTs against SARS-CoV-2 [31]. It has been reported that the lungs autopsies of patients with Covid-19 have high NTs infiltrations characterized by neutrophilic mucositis, acute capillaritis, and fibrin deposition with neutrophilic extravasations into the air space [8]. High NTs in the pulmonary microcirculation and the activated platelets are entrapped with subsequent degeneration and formation of NETs [8]. The expelled contents from deranged NTs such as free DNA, citrullinated histones, and myeloperoxidase (MPO) are deposited within NETs; some of these contents are released into the circulation, and their levels are correlated with NETs density and Covid-19 severity [32]. SARS-CoV-2, like other viruses, can directly trigger the formation of NETs by unidentified mechanism; however, indirect activation of NETs formation in Covid-19 might be due to SARS-CoV-2-induced CS and down-regulation of ACE2, which inhibits NTs infiltrations [33]. Indeed, formed ROS during SARS-CoV-2 infection directly activates both NETs formation inflammatory cascades in a vicious cycle [34] (Fig. 4).

4. Nets and acute lung injury in Covid-19

The NETs are highly toxic to the vascular endothelium and lung epithelial cells due to their contents, which are histones, MPO, defensins, and cathelicidins [18]. For example, histone has the robust cationic property that binds negative charge host cell membrane leading to cell lysis, tissue damage, and induction of inflammations [18]. Therefore, anti-histone antibody and neutrophil esterase blocking antibodies may reduce NETs-induced tissue damage and ALI [35]. Thereby, SARS-CoV-2-induced ALI and ARDS might be mediated by induction of NETs formation [213]. Yaqinuddin et al. [36] reported that excessive NETs development is related to the progression of ALI and ARDS due to the creation of the NETs-IL-1β loop that is exaggerated and can cause inflammatory-induced lung damage. NETs-IL-1β loop is developed due to activation of IL-1β by the NETs, and also IL-1β stimulates NETs formation [36]. As well, NETs-IL-1β loop is also created due to activation nod-like receptor pyrin 3 (NLRP3) inflammasome of lung macrophages by NETs during acute SARS-CoV-2 infection the macrophages extrude their contents to form macrophage extracellular traps (METs) similar to that of NETs [213]. NETs drive only pro-inflammatory macrophages (M1) to form METs in response to netting pulmonary NTs [37]. Formations of both NETs and METs in the lung are associated with localized lung pathology in a margined pool manner; however, in severe cases, this reaction may spill over and extend to the systemic circulation leading to more severe inflammatory reactions and development of complications [38]. From a clinical point of view, old age is a sovereign risk factor for the development of ALI and ARDS in SARS-CoV-2 infection [39], though NETs formation is reduced in the elderly [40]. The possible explanation of this phenomenon is that NETs formation is beneficial in the early stage to eliminate the invading virus; thus, SARS-CoV-2 infection may be exacerbated in a steady-state in the old-age group, causing more ALI ARDS and other complications [41].

On the other hand, platelets of elderly patients are unstable and prone to overactivation in triggering NTs for NETs formation [42]. Moreover, overstated management of ALI or ARDS by high-pressure oxygen therapy may increase the risk of more ALI through induction of NETs formation [43]. Alongside, lipid-lowering statins commonly
prescribed in the elderly Covid-19 patients are associated with enhancing NETs formation [44].

NETs formation has been linked to the development of different respiratory disorders including; asthma, cystic fibrosis, acute bacterial pneumonia, and chronic obstructive pulmonary disease (COPD) [45]. Experimental animal studies have shown the pathologic role of NETs in the induction of ALI, and loss of NETs contents and neutrophil granules may reduce the risk for the development of ALI in mice [18]. A recent mouse model revealed that released histone-DNA complexes of NETs activate macrophages and other immune cells through activation of TLR9 with subsequent stimulation the release of TNF-α activate macrophages and other immune cells through activation of mouse model revealed that released histone-DNA complexes of NETs activate macrophages and other immune cells through activation of TLR9 with subsequent stimulation the release of TNF-α [44]. Therefore, NETs formation during SARS-CoV-2 infection may cause ALI and ARDS directly or indirectly through activation of TNF-α, IL-6, and IL-1β with induction of CS [47]. During the development of CS, the pro-inflammatory cytokines lead to uncontrolled interactions between the NTs and macrophages with subsequent progressive inflammation [48]. IL-6 binds IL-6Rα to be intimate with the pro-inflammatory state; in this way, the NTs can shed IL-6Rα that augment the pro-inflammatory effect of IL-6 in the induction of CS-induced ALI [8].

In this context, aberrant NTs-induced CS in Covid-19 vastly differs from INF-induced CS in macrophage activation syndrome (MAS) [49]. However, uncontrolled NTs activation by PAMPs from SARS-CoV-2 infected cells may lead to robust activation of macrophages with a considerable amount of pro-inflammatory cytokines, which is linked with the development of ALI and ARDS [50]. Hu et al. [51] observed that NETs formation contributes to activation of MAS through activation of NLRP3 inflammasome in adult-onset Still disease.

Therefore, these findings revealed that aberrant NTs activation alone or through NETs formation might augment SARS-CoV-2-induced CS and MAS in patients with severe Covid-19. Wang et al.’s [52] retrospective study involving 55 Covid-19 patients illustrated that neutrophilia and NETs formation are correlated with ALI and high lung computed tomography score. Indeed, plasma levels of NETs are correlated with SARS-CoV-2 viral load and associated inflammatory cytokines and chemokines [53].

Thereby, these experimental and clinical studies document that neutrophilia and NETs formation are highly implicated in the pathogenesis of ALI and ARDS in severe Covid-19 (Fig. 5).

5. Nets and coagulopathy in Covid-19

It has been shown that severe SARS-CoV-2 infection is associated with coagulopathy and thrombosis, which might drive for Covid-19 severity [54]. Micro-vascular injury-induced endothelial dysfunction and the formation of anti-phospholipids antibodies could be the initial step in the development of disseminated intra-vascular thrombosis and localized pulmonary micro-thrombosis [55]. Coinciding with this notion, the biomarker of coagulopathy and fibrin degradation such as D-dimer is elevated and correlated with mortality in patients with severe Covid-19 [56]. Different studies proposed that NETs formation in Covid-19 might be the potential cause of venous and arterial thromboembolism due to vasculitis and immune-mediated mechanism [57]. A recent experimental study by Hisada et al. [58] confirmed that high plasma NETs level is associated with developing venous thrombosis in mice. However, the precise mechanism of NETs-induced thrombosis is ill-defined.

Nevertheless, diverse studies revealed that platelet activation and immune-mediated fibrin formation could be the proposed mechanisms [59]. During inflammatory reactions caused by dissimilar metabolic and infectious disorders, the platelets membrane-bound TLR4 are activated and interact with the NTs in the formation of NETs [59]. In this way, the NETs also activate the platelet via P-selectin, leading to platelet aggregation and thrombosis [60]. Notably, during mild SARS-CoV-2 infection, physiological immuno-thrombosis is developed and controlled by body homeostatic mechanism; however, in severe SARS-CoV-2 infections, uncontrolled physiological immuno-thrombosis may be controlled extend and develop into pathological immuno-thrombosis [61]. Besides, pathological immuno-thrombosis highly targets pulmonary and renal micro-circulations, leading to ALI [62] and acute kidney injury [63] in censorniously ill Covid-19 patients. Additionally, NETs formation in Covid-19 may induce- Kawasaki-like vasculitis and coagulopathy in infants and children with mild SARS-CoV-2 infections [64].

On the other hand, Skendros et al.’s [65] case-controlled study illustrated that activation of both NTs and complemented contribute to inducing thrombotic microangiopathy and hyperinflammation in patients with Covid-19. Complement activation drove immune cells, mainly monocytes, and NTs, to the site of lung injury, and in concert with platelets, can induce micro pulmonary thrombosis and systemic immuno-thrombosis [34]. Various studies showed that sera of Covid-19 patients contain a lot of immune complexes and autoantibodies that activate the complement cascade, mainly C3 [66]. Also, SARS-CoV-2 virions such as nucleocapsid protein can activate C3 through lectin dependent pathway [66]. Complement activations trigger tissue factor factor expression on the NT cell membrane with significant platelet activation leading to NETs formation and immuno-thrombosis [67]. Therefore, C3 inhibitor (AMY-101) inhibits immuno-thrombosis and thrombo-
inflammatory response to the SARS-CoV-2-induced microvascular injury [68].

Similarly, compstatin (C3 inhibitor) inhibits C3-induced formation of NTs-platelet complex and NETs production with subsequent suppression of micro-vascular thrombosis [69]. Therefore, C3 inhibitors may reduce NETs-induced immuno-thrombosis and the development of ALI and ARDS in patients with Covid-19 [70]. Indeed, NETs contents can directly lead to immuno-thrombosis and thrombo-inflammatory [70]. Middleton et al. [71] illustrated that the high MPO-DNA complex released from NETs in the plasma of Covid-19 patients is linked with pulmonary micro-thrombosis and ARDS. In addition, the interaction between NETs and platelet phospholipids activates the plasma kallikrein-kinin system leading to platelet aggregation and thrombosis [72]. Similarly, NETs histones activate platelets TLR causing platelet aggregations [73]. Alongside, progressive binding of NTs to the formed NETs contributes to digestion and degradation of tissue factor inhibitor and anti-thrombin III (natural anticoagulant), thereby augmenting the pro-coagulant activity of thrombin in the induction of intravascular thrombosis [74].

Moreover, NETs deliver extracellular oxidant contents such as nitric oxide synthase, NADPH oxidase, and MPO that serve as a potential source of toxic histones and DNA, which activate the extrinsic coagulation pathway [75]. In contrast, the tissue factor of NETs activates the intrinsic coagulation pathway [75,76]. In addition, neutrophil elastase is present in the NETs inactive tissue factor inhibitor leading to reduction of endogenous anticoagulant activity and augmentation of pro-coagulant activity [74]. Besides, exaggerated innate immune response-induced cytokine release in SARS-CoV-2 infection may lead to endothelial dysfunction and activation of the pro-coagulant cascade [77]. Furthermore, Zuo et al. [57] showed a positive correlation between NETs blood level and D-dimer, suggesting a potential link between NETs formation fibrin degradation products, and activated prothrombotic pathway.

Thus, a new perspective about the critical role of NETs in the induction and initiation of thrombosis and coagulopathy suggested that NETs act as a scaffold for thrombus formation through promoting erythrocyte and platelet adhesions by concentrating coagulation factors and effectors proteins [78]. Therefore, these findings highlighted the intricate relationship between endothelial dysfunction and platelet activation during NETs formation-induced thrombosis in patients with SARS-CoV-2 infection (Fig. 6).

6. Nets and comorbidities in Covid-19

Diabetes mellitus (DM), hypertension (HT), obesity, and other cardio-metabolic disorders are the commonest comorbidities risk factors that increase Covid-19 severity [79]. However, DM is regarded as one of the most distinctive risk factors for Covid-19 and 16.2% of patients with severe Covid-19 had DM, which might explain the high case fatality in diabetic Covid-19 patients [80]. This may be due to exaggerated pro-inflammatory response and dysfunction of innate immunity [80]. Hyperglycemia in DM primes NTs to release and form NETs; hyperglycemia also induces the NTs to produce Ca-binding protein S100 A8/A9 (S100A8/A9) that activates the release of hepatic thrombopoietin and subsequent thrombosis [81]. In addition, Th17-associated cytokines are increased in both DM and Covid-19 that trigger an exaggerated immune response and NETs formation [50]. Of note, exaggerated NETs formation due to underlying metabolic and inflammatory reactions in DM may lead to abnormal immune response and cytokine deregulation in SARS-CoV-2 infection [82].

Moreover, hyperglycemia and associated ROS lead to the pre-activation of NTs for the production and release of NETs when activated by various stimuli [83]. NTs from diabetic patients also produce more IL-6 and are more susceptible to NETs formation [83]. Hyperglycemia-induced NETs formation is performed through activation of NADPH oxidase in a concentration-dependent manner; therefore, NADPH oxidase inhibitors reduce NETs formation in DM [84]. Thus, NETs formation in diabetic patients with Covid-19 is exaggerated due to the dual effect of hyperglycemia and SARS-CoV-2 in activating NADPH oxidase [85]. Therefore, the net-final effect of DM in the augmentation of Covid-19 severity is might be the NETs formation.

On the other hand, cardiovascular diseases such as HT, endothelial dysfunction, coronary heart disease (CHD), acute cardiac injury (ACI) are common in comorbidities linked with Covid-19 severity [86]. These complications are developed due to direct SARS-CoV-2 injury or indirectly through ACE2 down-regulation and development of CS [86]. Exaggerated AngII level with reduction of vasodilator Ang1-7 due to AngII down-regulation and development of CS [86]. Alongside, down-regulation of ACE2 may increase NTs infiltration and NETs formation with subsequent endothelial injury-mediated thrombosis and pulmonary hypertension [88]. Li et al. [89] showed that patients with essential hypertension have a hypercoagulability status due to higher NETs formation. Indeed, NETs formation may exacerbate endothelial injury and coagulation in hypertensive patients [90]. Therefore, NETs formation might be the potential link between Covid-19 and HT [Fig. 7].

Similarly, NETs are intricated in the pathogenesis of acute myocardial injury (AMI) since NETs increase fibrin formation and deposition at the site of plaque rupture in the coronary vessels [91]. In this site, NETs
release functional tissue factors, which enhance platelet activation and thrombin generation [92]. In this way, the activated platelets promote NETs formation at the site of AMI [92]. Wei et al. ’s [93] prospective study involved 101 Covid-19 found that 15.8% of them presented with AMI and they needed mechanical ventilation, all of the patients had a poor prognosis. The fundamental mechanisms of AMI in Covid-19 might be due to direct SARS-CoV-2, SARS-CoV-2-induced down-regulation of ACE2, and SARS-CoV-2 -induced CS [94,95]. Kounis et al. [96] reported that AMI in Covid-19 might be due to activation and upregulation of prothrombotic factors such as NETs, von-Willebrand factor, factor VIII, and D-dimer. These observations shed light on the critical role of NETs as they link the pathogenesis of AMI and ARDS in Covid-19.

Furthermore, obesity, which is considered an inflammatory status due to adipose tissue dysfunction, is commonly associated with cardiovascular complications that increase the risk for Covid-19 [97,98]. NETs are increased in obesity due to augmentation of immune cell infiltrations into adipose tissue with subsequent chronic adipose tissue-mediated inflammatory reactions [99]. Therefore, NETs inhibitors may attenuate obesity-induced endothelial dysfunctions and coagulation disorders [100]. Surprisingly, platelet activations are reduced during sepsis in obesity with reducing of NETs formation [101]. Furthermore, experimental studies illustrated that a high-fat diet increases the expression of cathelicidin, a specific marker of NETs formation in mice [102]. Therefore, obesity-mediated NETs formation and endothelial injury might raise the risk of coagulopathy in SARS-CoV-2 infection [103]. Since MPO-DNA complexes linked with immunothrombosis are elevated in obese patients and do not return to the baseline level even after gastrectomy, since reduction in the body weight and body mass index did not affect immunological reactivity of NTs and propensity for NETs formation [104]. Taken together, cardio-metabolic comorbidities may increase Covid-19 severity mainly through potentiating of NETs formation that amplifies the risk of coagulopathy, ALI, and ARDS [105].

Fig. 7. Neutrophil extracellular traps and hypertension.

Fig. 8. Different effects of activated neutrophil extracellular traps in Covid-19.
Taken together, NETs formation lead to diverse effects in SARS-CoV-2 infection that can cause different complications [Fig. 8].

7. Nets inhibitors as a therapeutic modality for Covid-19

7.1. Endogenous NETs inhibitors

Endogenous NETs inhibitors such as neonatal NET-inhibitory factor (nNIF) inhibit the critical factors in NETs formation such as histone citrullination, nuclear condensation, and activity of peptide arginine deiminase 4 (PAD4) [106]. Also, nNIF inhibits pathogens, and microbibal toxins-mediated NETs formation, thereby reducing systemic inflammation-induced collateral tissue damage [106]. Campbella et al.’s [107] study illustrated that nNIF is highly circulated in fetal circulation and generated by the action of placental alpha-1-antitrypsin. This nNIF is responsible for immunological tolerance during the transition from intrauterine to extrauterine life, so NETs isolated from the umbilical cord of preterm neonates are defective for NETs formation and bacterial killing [108]. Furthermore, it has been shown that nNIF may attenuate respiratory syncytial virus infection-induced NETs formation in the preterm neonate [109]. Pertiwi [110] suggests that nNIF might be a promising agent targeting NETs in managing Covid-19 severity.

Prostaglandins (PGs) are eicosanoids synthesized in the body by the action of cyclooxygenase (COX) enzyme from arachidonic acid (AA) [111]. PGE2 is the most abundant one has both inflammatory and anti-inflammatory actions [112]. It has been reported that PGE2 inhibits NETosis and NETs formation through activation of protein kinase A and cAMP that are potent inhibitors of NETs formation [113]. It has been shown that over-expression of COX2 in the NETs is associated with the defective killing of intracellular pathogens due to reduction in NETs formation [114]. Therefore, the PGE2 antagonist restores NETs formation [114].

Moreover, a peptide inhibitor (PA-Dpeg24) of complement C1-dependent MPO activation inhibits inflammatory reactions and NETs formation in the transplanted tissues [115]. Therefore, PGE2 inhibits NETs formation through attenuation of complement activation. However, PGE2 serum level is increased in Covid-19, and COX-2 inhibitors might be beneficial in the restoration of human immune response [116]. Inhibition of COX-2 is associated with the elevation of AA, an endogenous antiviral substance associated with inhibiting enveloped viruses such as SARS-CoV-2 and human immune deficiency (HIV) [117]. Therefore, there is a controversy about the potential role in the management of SARS-CoV-2-induced NETs formation.

Thrombomodulin is a cofactor protein mainly expressed on the vascular endothelial cells, modulates thrombin activity [118]. Thrombomodulin-thrombin complex stimulates protein kinase C, which is essential for the anticoagulant pathway [118]. It decreased in sepsis and severe viral infection due to its downregulation by inflammatory cytokines [119]. NETs block fibrinolysis and activate aggregation of platelets, erythrocytes, fibrin, and other clotting factors in the induction of immuno-thrombosis [120]. Recombinant human thrombomodulin (rhTM) inhibits NETosis and NETs formation [120]. Shrestha et al. [121] showed that rhTM inhibits histone-induced NETs release in vitro and in vivo. Also, rhTM attenuates NETs-induced ALI by reducing NETs accumulation and toxic effects of histone [122]. In Covid-19, SARS-CoV-2 infection is related to high inflammatory cytokine angiopoietin-2 (ANGPT2), which inhibits thrombomodulin-thrombin complex with reduction of physiological anticoagulant [123]. It has been hypothesized by Mazzeffi et al. [124] that administration of rhTM in critically Covid-19 patients may reduce ALI/ARDS via inhibition of NETs formation-induced coagulopathy.

Activated protein C (APC), a serine protease enzyme, has anti-inflammatory, cytotoxic, and anti-coagulant effects [125]. APC inhibits the release of extracellular histone, activation of clotting factors, and NETs accumulation and formation [125]. Different preclinical studies demonstrated that APC inhibits thrombin generation and excessive inflammation and ischemic-reperfusion-induced tissue injury in bacterial pneumonia [126]. APC also has a protective effect against the development of SARS-CoV-2-induced endothelial injury and coagulopathy via suppression of NETs formation [127]. Guglielmetti et al. [128] offered that recombinant APC might be a therapeutic strategy in Covid-19 through inhibiting inflammation and associated coagulopathy. In critically Covid-19 patients, severe inflammation and thrombosis are the primary determinant factors due to deficiency of APC [129]. In a case series of 10 Covid-19 patients’ activities of APC and anti-thrombin are reduced with significant elevation of factor VIII and fibrinogen plasma levels, suggesting a state of hypercoagulability in critically severe Covid-19 patients [130]. Therefore, APC-based therapy is recommended in severely Covid-19 patients to prevent NETs-induced inflammation and coagulopathy.

Anti-high mobility group box-1 (HMGB1) is an endogenous protein released from platelets. It has pro-inflammatory action and regulates NTs chemotaxis [131]. HMGB1 induces thrombus formation, NETosis, and NETs formation through C5a-dependent activation of platelet-neutrophil interaction [131]. Exposure of NTs to the higher concentration of HMGB1 results in NETs formation in vitro [132]. Therefore, anti-HMGB1 antibodies may inhibit NETs formation with reduction of circulating DNA-histone complexes [133]. Moreover, anti-HMGB1 antibodies inhibit NETs formation and pro-inflammatory induced-ALI [134]. Street [135] observed that HMGB1 activates autophagy which is concerned with SARS-CoV-2 entry and replication [136]. Also, down-regulation of ACE2 by SARS-CoV-2 elicits activation of the HMGB1 pathway with subsequent activation of cytokine storm-induced-ALI/ARDS [136]. Therefore, HMGB1-inhibitors such as hydroxychloroquine, methotrexa, glyceryrrizin, inf flourishing salicylic acid derivative might reduce Covid-19 severity [136]. Into the bargain, Dinicolantoio et al. [137] showed that melatonin improves the activity of type I immune response through inhibition of the HMGB1 signaling pathway during SARS-CoV-2 infection. Therefore, HMGB1 is regarded as a target for repurposing drugs in the management of Covid-19.

C1 esterase inhibitor (CIE-INH) is an endogenous inhibitor of the C1 component of the complement system, regulating the kallikrein system and coagulation pathway [138]. CIE-INH is approved for the management of hereditary angioedema and may reduce NETs-mediated ALI [139]. In addition, CIE-INH blocks histone, NETosis, and NETs formation, thereby reducing the risk of ALI/ARDS [140]. Thomson and his colleagues reported that SARS-CoV-2 infection is linked with deficiency of CIE-INH, and rapid improvement in Covid-19 is observed following treatment with CIE-INH [141]. However, an ongoing clinical trial in hospitalized Covid-19 patients is waiting to observe the clinical benefit of conestat alfa (CIE-INH) in treating and preventing SARS-CoV-2 infection [142]. The Brazilian clinical trial started in May 2020 and is expected to be completed in April 2021, using CIE-INH and icatibant (bradykinin inhibitor) to manage Covid-19 [142]. Thus, recombinant CIE-INH might be a possible therapy in the management of patients with severe Covid-19.

Heparin is a natural glycosaminoglycan used as an anticoagulant in managing ischemic heart disease, stroke, and deep vein thrombosis [143]. Heparin attenuates NETosis and NETs formation with reduction of circulating histone and associated NF-kB activation in different inflammatory diseases [144]. Moreover, non-anticoagulant heparin (parnaparin) could be used to manage histone and NETs-induced inflammatory diseases [144]. In addition, heparin has a beneficial effect in managing Covid-19 through endothelial protection and prevention of coagulopathy [145]. However, resistance to the heparin effect may develop in severe Covid-19 due to auto-antibody against activated factor X [146]. Thus, high doses of heparin or switching to low molecular weight heparin are recommended [146]. Nonetheless, heparin therapy has a potential role in managing severe Covid-19 through anti-inflammatory, anti-NETs, improvement of lung oxygenation, and prevention development of ARDS [147].

Human DNAase is a selective enzyme that cleaves and hydrolyzes
human DNA in the sputum and mucous, promoting sputum clearance and reducing bronchial secretions’ viscosity [148]. Recombinant human DNAase (rhDNAase) has acute anti-inflammatory effects by suppressing NETosis and NETs formation, reducing NTs infiltrations and expression of thrombin [149]. Wang et al. [150] illustrated that rhDNAase effectively treats severe sepsis by inhibiting ROS and NETs formation. Therefore, rhDNAase effectively reduces the period of mechanical ventilation in critically severe Covid-19 patients [151].

7.2. Exogenous NETs inhibitors

Antibiotics may have immunomodulating effects through suppression of NETosis and NETs formation and release of pro-inflammatory cytokines [152]. Azithromycin and other macrolides and chloramphenicol have significant anti-inflammatory effects through inhibition of NETs formation [153]. Furthermore, it has been illustrated that azithromycin inhibits cytokine production, mucin secretion, and bronchial cell proliferation by inhibiting mitogen-activated protein kinase (MAPK) and downstream of the NF-κB pathway [154]. These immunomodulating effects of azithromycin make it a potential candidate in the management of Covid-19 [155]. Furthermore, doxycycline also blocks NETosis and NETs formation with significant immunomodulating effects; thus, it can be used effectively in Covid-19 [156]. Therefore, the pleiotropic effects of antibiotics, mainly anti-inflammatory and immunomodulatory effects and anti-SARS-CoV-2 effect, can subsidize in controlling severe Covid-19 patients [155].

Aspirin (acetylsalicylic acid) is a non-steroidal anti-inflammatory drug (NSAID), has anti-inflammatory and anti-thrombotic effects used in the treatment of various inflammatory disorders [157]. Aspirin inhibits PGs synthesis and causes irreversible acetylation of platelets COX with suppression of thromboxane A2 leading to a noteworthy antiplatelet effect [158]. Furthermore, different studies showed that aspirin inhibits NETosis and platelet activations and NETs formation [159]. During inflammatory conditions, the platelets are activated through TLR2/TLR4, leading to the expression of P-selectin, which induces NTs for NETs formation. In addition, activated platelets secret HMBG-1 and platelet factor 4 that together induce NTs for NETs formation [160]. Therefore, aspirin and other antiplatelet inhibits NTs-platelets interactions and formation of intravascular NETs during endotoxemia-induced ALI [161]. Aspirin also has a direct inhibitory effect on NETs formation via suppression of NTs NF-κB pathway [162]. Recently, aspirin improved clinical outcomes in critically hospitalized Covid-19 patients on mechanical ventilation through suppression of NF-κB pathway and SARS-CoV-2-induced NETs formation [163]. Taken together, aspirin is an effective drug in the prevention of SARS-CoV-2-induced ALI and MOF through mitigation of inflammatory reactions and NETs formation [164].

Sivelestat (ONO-5046) is a competitive, reversible, and selective inhibitor of neutrophil elastase (NEase), not affecting other cellular proteases’ activity [165]. Different experimental and preclinical studies showed that sivelestat is effective against ARDS by regulating lung vascular permeability, pulmonary pressure, pathogen clearance, and neutrophil-mediated lung epithelial injury [166]. Okayama et al.’s [167] clinical study observed that sivelestat improves pulmonary function, shortens the duration of mechanical ventilation, and oxygen saturation in patients with systemic inflammatory syndrome and ARDS. Furthermore, Miyoshi et al. [168] illustrated that sivelestat combined with recombinant human soluble thrombomodulin effectively mitigates disseminated intravascular coagulopathy-induced ARDS in intensive care unit (ICU) patients, it increases survival and ventilator-free period. Therefore, sivelestat might be a promising therapy in managing Covid-19-induced ALI, ARDS, and coagulopathy through inhibition of NEase and NETs formation [169]. In addition, sivelestat might be an effective preventive therapy against Covid-19-induced ARDS when given in lymphocytopenic patients before developing neutrophilia and NETs formation [170]. Also, it prevents activation of SARS-CoV-2 S protein and binding with ACE2 [170].

Chloramidine is an inhibitor of protein arginine deiminase (PAD), which is involved in NETs formation and regulation of immune response [171]. Also, chloramidine reduces NETs formation mediated systemic inflammations in the experimental animals [172]. Recently, it has been shown that PAD inhibitors mitigate inflammatory disorders in multiple myeloma [173]. Therefore, chloramidine and other PAD inhibitors reduce NETs formation in different viral infections [174]. Furthermore, up to date, Du et al. [175] illustrated that PAD inhibitors might prevent ALI via suppression of NETs formation. Therefore, chloramidine and other PAD inhibitors might be of potential therapeutic role in managing Covid-19 through suppression of NETs-induced inflammatory burst and coagulopathy [176].

Cyclosporine A is an immunosuppressant agent used to manage autoimmune diseases and organ transplants [177]. It binds cellular cyclophilin and inhibits activated T cell’s calcineurin pathway nuclear factor with subsequent inhibition of NETs formation [178]. However, inhibiting NETosis by cyclosporine A may impair the immune response to invading pathogens [179]. In the Covid-19 era, cyclosporine A effectively mitigates exaggerated immune response and cytokine storm with impairment of viral pathogenesis [177,180].

Diphenyleneiodonium chloride (DPI) is an oral hypoglycemic drug that inhibits gluconeogenesis and oxidative stress by inhibiting NADPH oxidase, xanthine oxidase, nitric oxide synthase, and oxidoreductase [181]. It has been proposed that DPI may inhibit the release of extracellular DNA and block NETs formation [182]. In addition, DPI exerted potential antiviral effects via suppression of Zika virus-induced NETs formation [183]. Therefore, DPI may reduce SARS-CoV-2-mediated NETs formation and link ALI and immunothrombosis [184,185].

Metformin is an insulin-sensitizing agent and is regarded as first-line therapy in managing type 2 diabetes mellitus (T2DM) [79]. It acts through the activation of the AMPK pathway that increases cellular glucose uptake (1 9 5). In addition, Metformin inhibits oxidative stress and the release of pro-inflammatory cytokines through the AMPK pathway-dependent suppression of the mTORC1 signaling pathway [186]. In addition, Metformin has immunoregulating effects via inhibition of NETosis and NETs formation [187]. Recently, Metformin reduces SARS-CoV-2 pathogenesis and NETs formation with subsequent reduced risk of ALI/ARDS in Covid-19 [188].

Hydroxychloroquine is an antimalarial agent with immunosuppressive and immunomodulating effects used to treat parasitic infections and autoimmune disorders [189]. It inhibits NTs phagocytosis, macrophage activity, and the release of pro-inflammatory cytokines [190]. Hydroxychloroquine suppressed platelets activation and aggregation induced by inflammatory mediators and thrombin [191] and is regarded as an anti-thrombotic agent in anti-phospholipid syndrome [192]. It has been reported that hydroxychloroquine can interfere with NETosis and NETs formation through clocking TLR9 in mice [193]. Boone et al. [194] observed that hydroxychloroquine attenuates hypercoagulability through inhibition of NETs formation. Therefore, hydroxychloroquine may reduce SARS-CoV-2-induced ALI and cytokine storm by inhibiting inflammatory burst and NETs formation [195]. Thus it can be used effectively in the prevention and treatment of Covid-19 [195]. The up-to-date foundation shows that hydroxychloroquine does not affect clinical outcomes and mortality in patients with Covid-19. Still, it is effective as a potential prophylactic agent in the early stage of SARS-CoV-2 infection [196].

N-acetylcysteine (NAC) is a mucolytic agent that decreases mucous viscosity used in the management of paracetamol poisoning, COPD, and oxidative stress treatment [197]. In addition, NAC inhibits ROS-induced NETosis and NETs formation [198] and thrombosis. Thus it may block immunothrombosis in different inflammatory disorders [199]. Recently, NAC has been effective against SARS-CoV-2 infection via interruption of viral replica and development of cytokine storm [200]. In addition, NAC mitigates SARS-CoV-2-induced oxidative stress and endothelial injury and associated coagulopathy through regeneration of endogenous
glutathione [201]. Vitamin D is a fat-soluble secosteroid involved in regulating Ca$^{2+}$ level and bone mineralization [202]. Vitamin D reduces COPD, respiratory viral infections, pulmonary tuberculosis, and metabolic disorders [203]. Moreover, Vitamin D has immunomodulating effects; it blocks NETosis and NETs formation and regulates innate immune response with inhibition release of pro-inflammatory cytokines [204]. Thus, Vitamin D supplementation may reduce Covid-19 mortality and severity via suppression of cytokine storm and regulation of innate immunity against SARS-CoV-2 infection [205].

8. Conclusion

NETs formation in SARS-CoV-2 infection is linked with critical complications, including ALI and ARDS, due to the development of hyperinflammation, cytokine storm, and immunothrombosis. Therefore, anti-NETs pharmacotherapy might be a promising goal in the management of patients with severe Covid-19. Additional in vitro and in vivo studies and clinical trials and prospective studies are recommended in this regard.

Funding

There is no funding.

Declaration of Competing Interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

References

[1] H.M. Al-Kuraishy, A.I. Al-Gareeb, M. Alshihed, N. Cruz-Martins, G.E. Batista, COVID-19 and Risk of Acute Ischemic Stroke and Acute Lung Injury in Patients With Type II Diabetes Mellitus: The anti-inflammatory role of Melatonin, Front. Med. 19 (8) (2021 Feb) 110.

[2] H.M. Al-Kuraishy, A.I. Al-Gareeb, N. Qusti, N. Cruz-Martins, G.E. Batista, Sequential dosyccline and colchicine combination therapy in Covid-19: The salutary effects, Pulmon. Pharmacol. Ther. 14 (2021 Mar), 102008.

[3] H.M. Al-Kuraishy, A.I. Al-Gareeb, N. Cruz-Martins, G.E. Batista, Hyperbilirubinemia in Gilbert syndrome attenuates Covid-19 induced-metabolic disturbances: A case-report study, Front. Cardiovascular Med. 8 (2021) 71.

[4] H. Al-kuraishy, A.I. Al-Gareeb, K.J. Alzahrani, N. Cruz-Martins, G.E. Batiha, The looming effects of estrogen in Covid-19: A Rocky Rollout, Front. Nutrition 8 (2021) 82.

[5] T. Sharma, M. Abokhastir, M.H. Baig, J.J. Dong, M.S. Alam, I. Ahmad, S. Irfan, Screening of drug databank against WT and mutant main protease of SARS-CoV-2: Towards finding potential compound for repurposing against COVID-19, Saudi J. Biol. Sci. (2021).

[6] H.M. Al-Kuraishy, N.R. Hussien, M.S. Al-Naimi, A.K. Al-Buhadily, A.I. Al-Gareeb, C. Langnier, Renin-Angiotensin system and fibrinolytic pathway in COVID-19: One-way skepticism, Biomed. Biotechnol. Res. J. (BBRJ) 4 (5) (2020 Aug) 33.

[7] H.M. Al-Kuraishy, A.I. Al-Gareeb, M.S. Al-Niemi, A.K. Al-Buhadily, N.A. Al-Mosawi, H.M. Al-Kuraishy, A.I. Al-Gareeb, M.S. Al-Niemi, A.K. Al-Buhadily, N.A. Al-Mosawi, H.M. Al-Kuraishy, A.I. Al-Gareeb, N. Cruz-Martins, E.S. Batiha, The looming effects of estrogen in Covid-19: A Rocky Rollout, Front. Nutrition 8 (2021) 82.

[8] M.J. Raftery, P. Lalwani, E. Krautkr...
89. J. Li, D. Tong, Y. Wang, Y. Liu, X. Zhang, N. Liu, S. Wang, Y. Xu, Y. Li, X. Yin, H.M. Al-Kuraishy, A.I. Al-Gareeb, G. Mostafa-Hedeab, K.I. Kasozi, G. Zirintunda, H.M. Al-Kuraishy, O.M. Sami, N.R. Hussain, A.I. Al-Gareeb, Metformin and/or pioglitazone attenuates COVID-19: a case series, J. Adv. Pharm. Technol. Res. 11 (3) (2020 Jul) 142.

90. M.J. Kraakman, M.K. Lee, A. Al-Shaera, D. Goraljevic, T.J. Barrett, E. Montenont, D. Basu, S. Heywood, H.L. Kammoun, M. Flynn, A. Whillas, Neutrophil-derived S100 calcium-binding proteins A8/A9 promote reticulated platelet microplatelets in mice bearing human pancreatic tumors, Haematologica 105 (1) (2020 Jan) 218.

91. E. Lariand, K. Martindal, S.F. Lax, K. Skok, P. Zechner, H.H. Kessler, N. Kaufmann, C. Koelblinger, S. Qusti, E.M. Alshammari, E.T. Ayikobua, D. Ng, S.P. Salvatore, M. Mostyka, A. Baxter-Stoltzfus, A.C. Borczuk, M. Loda, M.J. Cody, Neutrophil extracellular traps contribute to immunothrombosis in COVID-19 acute respiratory distress syndrome, Blood, J. Am. Soc. Hematol. 136 (10) (2020 Sep) 3119-3129.

92. J. Perez-Galarza, C. Prin, O. Chevallet, G. Bigliardi, A. Cauda, Ph. Guenet, J. Jeannin, B. Planche, A. Kafatos, N. Montravers, P. Thibodeau, P. Mariat, P. Topino, F. Dupont, S. Million, G. Cacoub, F. Girard, Neutrophil extracellular traps promote thrombin generation through platelet-dependent and platelet-independent mechanisms, Arterioscler. Thromb. Vasc. Biol. 34 (9) (2014 Sep) 1977–1984.

93. M. Moubarak, M. Saeed, H.H. Hetta, H.M. Al-Kuraishy, A. Al-Gareeb, Neutrophil extracellular traps contribute to immunothrombosis in COVID-19 acute respiratory distress syndrome, Blood, J. Am. Soc. Hematol. 136 (10) (2020 Sep) 3120-3129.

94. H. Qi, S. Yang, L. Zhang, Neutrophil extracellular traps and endothelial dysfunction in atherosclerosis and thrombosis, Front. Immunol. 7 (8) (2017 Aug) 2453.

95. H.M. Al-Kuraishy, A.I. Al-Gareeb, N. Qusti, E.M. Alshammari, G. Al-Bataih, Injury of Sarcopenia in Sarcopenia and COVID-19: An innovative perspective, Biomed. Pharmacother. 1 (143) (2021 Nov) 112913.

96. S.F. Lax, K. Skok, P. Zechner, H.H. Kessler, N. Kaufmann, C. Koelblinger, E. Montenont, D. Basu, S. Heywood, H.L. Kammoun, M. Flynn, A. Whillas, Neutrophil-derived S100 calcium-binding proteins A8/A9 promote reticulated platelet microplatelets in mice bearing human pancreatic tumors, Haematologica 105 (1) (2020 Jan) 218.

97. E. Lariand, K. Martindal, S.F. Lax, K. Skok, P. Zechner, H.H. Kessler, N. Kaufmann, C. Koelblinger, K. Vander, U. Bargfrieder, M. Trauner, Pulmonary arterial thrombosis in COVID-19: A case series, Ann. Intern. Med. 173 (5) (2020 Sep 1) 350-361.

98. W.J. Guan, Z.Y. Ni, Y. Hu, W.H. Liang, C.Q. Ou, J.X. Lei, H. Liu, H. Shan, C.L. Wei, D.S. Hui, B. Du, Clinical characteristics of coronavirus disease 2019 in China, N. Engl. J. Med. 382 (18) (2020 Apr 30) 1708-1720.

99. C.S. Young, S.R. Clark, A.C. Ma, S.A. Tavener, B. McDonald, Z. Goodarzi, M.M. Kelly, K. Vander, U. Bargfrieder, M. Trauner, Pulmonary arterial thrombosis in COVID-19: A case series, Ann. Intern. Med. 173 (5) (2020 Sep 1) 350-361.

100. H.M. Al-Kuraishy, A.I. Al-Gareeb, N. Qusti, E.M. Alshammari, G. Al-Bataih, Injury of Sarcopenia in Sarcopenia and COVID-19: An innovative perspective, Biomed. Pharmacother. 1 (143) (2021 Nov) 112913.

101. S.F. Lax, K. Skok, P. Zechner, H.H. Kessler, N. Kaufmann, C. Koelblinger, E. Montenont, D. Basu, S. Heywood, H.L. Kammoun, M. Flynn, A. Whillas, Neutrophil-derived S100 calcium-binding proteins A8/A9 promote reticulated platelet microplatelets in mice bearing human pancreatic tumors, Haematologica 105 (1) (2020 Jan) 218.

102. W.J. Guan, Z.Y. Ni, Y. Hu, W.H. Liang, C.Q. Ou, J.X. Lei, H. Liu, H. Shan, C.L. Wei, D.S. Hui, B. Du, Clinical characteristics of coronavirus disease 2019 in China, N. Engl. J. Med. 382 (18) (2020 Apr 30) 1708-1720.

103. E.A. Middleton, X.Y. He, F. Denorme, R.A. Campbell, D. Ng, S.P. Salvatore, M. Mostyka, A. Baxter-Stoltzfus, A.C. Borczuk, M. Loda, M.J. Cody, Neutrophil extracellular traps contribute to immunothrombosis in COVID-19 acute respiratory distress syndrome, Blood, J. Am. Soc. Hematol. 136 (10) (2020 Sep) 3119-3129.

104. S. Oehmcke, M. Mergelin, H. Herwald, Activation of the human contact system and clot stability, but does not prevent clotting, Perfusion (2021), 782.

105. J. Perez-Galarza, C. Prin, O. Chevallet, G. Bigliardi, A. Cauda, Ph. Guenet, J. Jeannin, B. Planche, A. Kafatos, N. Montravers, P. Thibodeau, P. Mariat, P. Topino, F. Dupont, S. Million, G. Cacoub, F. Girard, Neutrophil extracellular traps promote thrombin generation through platelet-dependent and platelet-independent mechanisms, Arterioscler. Thromb. Vasc. Biol. 34 (9) (2014 Sep) 1977–1984.

106. M. Moubarak, M. Saeed, H.H. Hetta, H.M. Al-Kuraishy, A. Al-Gareeb, Neutrophil extracellular traps contribute to immunothrombosis in COVID-19 acute respiratory distress syndrome, Blood, J. Am. Soc. Hematol. 136 (10) (2020 Sep) 3120-3129.

107. H. Qi, S. Yang, L. Zhang, Neutrophil extracellular traps and endothelial dysfunction in atherosclerosis and thrombosis, Front. Immunol. 7 (8) (2017 Aug) 2453.

108. H.M. Al-Kuraishy, O.M. Sami, N.R. Hussain, A.I. Al-Gareeb, Metformin and/or vildagliptin mitigate type II diabetes mellitus induced-oxidative stress: the intriguing effect, J. Adv. Pharm. Technol. Res. 11 (3) (2020 Jul) 142.

109. W.J. Guan, Z.Y. Ni, Y. Hu, W.H. Liang, C.Q. Ou, J.X. Lei, H. Liu, H. Shan, C.L. Wei, D.S. Hui, B. Du, Clinical characteristics of coronavirus disease 2019 in China, N. Engl. J. Med. 382 (18) (2020 Apr 30) 1708-1720.

110. C.S. Young, S.R. Clark, A.C. Ma, S.A. Tavener, B. McDonald, Z. Goodarzi, M.M. Kelly, K. Vander, U. Bargfrieder, M. Trauner, Pulmonary arterial thrombosis in COVID-19: A case series, Ann. Intern. Med. 173 (5) (2020 Sep 1) 350-361.

111. H.M. Al-Kuraishy, A.I. Al-Gareeb, N. Qusti, E.M. Alshammari, F. Sempé, Neutrophil extracellular traps contribute to immunothrombosis in COVID-19 acute respiratory distress syndrome, J. Clin. Investig. 127 (6) (2017 Jun 13) 2531-2542.
[91] Z. Zhou, S. Zhang, S. Ding, M. Abudupatar, Z. Zhang, X. Zhu, W. Zhang, Y. Zou, X. Yang, J. Ge, T. Hong. Excessive neutrophil extracellular trap formation aggravates acute myocardial infarction in apolipoprotein E deficiency mice via the ROS-dependent pathway, Oxidative Med. Cell. Longevity. 2019 (2019).

[92] K. Egbalzadeh, L. Georgi, T. Liu, T. Shang, Z. Li, T. Liu, C. S. Yost, M. J. Cody, E. S. Harris, N. L. Thornton, A. M. McInturff, M. L. Martinez, R. A. Campbell, M. Cody, Y. Kosaka, H. D. Campbell, C. Yost. Placental HTRA1 in inflammation and prostaglandins, Front. Cell. Neurosci. 1 (2018 Feb) 26.

[93] Y. Kondoh, A. Kosuma, Y. Nio, T. Oghara, T. Takamatsu, T. Ito. Prognostic implications of myocardial injury in patients with and without COVID-19 infection treated in a university hospital, Revista Española de Cardiología (English Edition) 74 (1) (2021 Jan) 24–32.

[94] M.S. Al-Niemi, H.M. Al-Kuraishy, A.J. Al-Gareeb, M. Alexiou, G.E. Batiha. Testosterone deficiency and COVID-19: an evidence-based review, Front. Immunol. 6 (2015) 1414. doi: 10.3389/foimm.2015.01414.

[95] Y. Wang, Q. Wang, J. Venugopal, J. Wang, X. Wang, Y. Han, H. Wang, T. Wang. Neutrophil extracellular trap (NET) formation: a novel innate immune deficiency in COVID-19 patients, Front. Immunol. 10 (2019 Oct) 2313.

[96] J.L. Vincent, B. Francois, I. Zabolotskikh, M.K. Daga, J.B. Lascarrou, M.Y. Kirov, A. Tabatabai, J. Menaker, R. Madathil, S. Galvagno, A. Menne, J.H. Griffin, P. Lyden. COVID-19 hypothesis: Activated protein C for therapy of neutrophil extracellular trap formation, J. Thromb. Haemost. 18 (7) (2020) 1738–1742.

[97] W. Dietz, C. Santos-Burgoa. Obesity and its implications for COVID-19 mortality, Obesity 28 (6) (2020) 1005.

[98] H.M. Al-Kuraishy, A.I. Al-Gareeb, H. Faidah, A. Alexiou, G.E. Batiha. Effect of orlistat alone or in combination with E2, Am. J. Respir. Crit. Care Med. 193 (2) (2016 Jan) 186–194.

[99] N. Ballinger, M. Xia, S. Murray, M.J. Kaplan, G.A. Yanik, B.B. Moore. Inhibition of neutrophil extracellular trap formation by platelets present high mobility group box 1 to neutrophils, inducing autophagy and promoting the extrusion of neutrophil extracellular traps, J. Thromb. Haemost. 12 (12) (2014 Dec) 2074–2088.

[100] G. Guglielmetti, M. Quaglia, P.P. Sainaghi, L.M. Castello, R. Vaschetto, M. Pirisi. Interleukin-1β in patients with COVID-19 infection treated in a university hospital, Revista Española de Cardiología (English Edition) 74 (1) (2021 Mar) 197–208.

[101] M. Hoxha, What about COVID-19 and arachidonic acid pathway? Eur. J. Clin. Invest. 51 (3) (2020 Apr 1) 282–289.

[102] M. Phelps, D.M. Christensen, T. Gerds, E. Fosba, J.H. Griffin, P. Lyden. COVID-19 – is retinoic acid an opportunity for adjunctive intervention in COVID-19? Anesth. Analg. (2020) 1–8.

[103] J. Hanley, C. Pay, J. Ewbank, J. Thomas, A. Mitrugas, S. Kadow, T. Takahashi, T. Chiu, X. Xu, A. Gruber, F. Lupu, J.H. Griffin. Activated protein C inhibits neutrophil extracellular trap formation in vitro and activation in vivo, J. Biol. Chem. 292 (21) (2017 May) 8616–8629.

[104] W.L. Macias, S. Yan, M. Wei, Y. Lin, G.E. Sandwsky, D.S. Ballard, J. M. Planquius, New insights into the protein C pathway: potential implications for the biological activities of drotrecogin alfa (activated), Crit. Care 9 (4) (2005 Aug) 1–9.

[105] J.H. Griffin, P. Lyden, COVID-19 hypothesis: Activated protein C for therapy of virus-induced pathologic thromboinflammation, Res. Pract. Thromb. Haemostasis 4 (4) (2020) 506–509.

[106] G. Guglielmetti, M. Quaglia, P.P. Sainaghi, L.M. Castello, V. Parichetti, M. Pirisi, F. Dell’Aste. COVID-19 hypothesis: Activated protein C for therapy of virus-induced pathologic thromboinflammation, Res. Pract. Thromb. Haemostasis 4 (4) (2020) 506–509.

[107] A. Tabatabai, J. Rabin, M. Renker, M. Dabestani, S. Gholam, A. Meri, S. Dabestani, E. Noiri, M. Nangaku. Neutrophil extracellular trap formation, Front. Immunol. 29 (10) (2019 Oct) 1–5.

[108] J.L. Vincent, B. Francois, I. Zabolotskikh, M.K. Daga, J.B. Lascarrou, M.Y. Kirov, A. Tabatabai, J. Menaker, R. Madathil, S. Galvagno, A. Menne, J.H. Griffin. Activated protein C inhibits neutrophil extracellular trap formation in vitro and activation in vivo, J. Biol. Chem. 292 (21) (2017 May) 8616–8629.

[109] M. E. Street, HMGB1: a possible crucial therapeutic target for COVID-19? J. Intensive Care 4 (1) (2016 Dec) 1–5.

[110] B. Shrestha, T. Ito, M. Kakuuchi, T. Totsuka, N. Nakagoshi, M. Yamamoto, I. Maruyama. Recombinant thrombomodulin suppresses histone-induced neutrophil extracellular trap formation, Front. Immunol. 29 (10) (2019 Oct) 5–9.

[111] P.S. Hair, A.J. Enos, N.K. Krishna, K.M. Cunnion. Inhibition of immune complex complement activation and neutrophil extracellular trap formation by peptide immunization, Front. Immunol. 26 (9) (2018 Mar) 555.

[112] M. Hosha, What about COVID-19 and arachidonic acid pathway? Eur. J. Clin. Pharmacol. 76 (11) (2020 Nov) 1501–1504.

[113] U.N. Das, Can bioactive lipids inactivate coronavirus (COVID-19)? Arch. Med. Res. 50 (1) (2020 Apr 1) 31–40.

[114] K. Eghbalzadeh, L. Georgi, T. Louis, H. Zhao, U. Keser, C. Weber, M. Mollenhauer. Prostaglandins in marine invertebrates, J. Biogeogr. 44 (10) (2017 Oct) 1979–1986.

[115] R. Kang, Q. Zhang, W. Hou, Z. Yan, R. Chen, J. Bonaroti, P. Bansal, T.R. Billiar, M. Hoxha, What about COVID-19 and arachidonic acid pathway? Eur. J. Clin. Investig. 51 (3) (2020 Apr 1) 282–289.

[116] J.J. Solomon, D. Kowalczyk, A. Nowak, A. Aras, A. Kowalczyk, M. Bocan, J. Autys, B. Bocan, K. Kijewska, M. Jankowski, J. Kozlowski, A. Kowalczyk, M. Bocan. Melatonin may decrease risk for and aid treatment of COVID-19 and other RNA viral infections, Open Heart 8 (2021) e001568. https://doi.org/10.1136/openheart-2020-001568.

[117] A. Panagiotou, M. Trendelenburg, M. Osthoff, The limbic pathway of complement in acute ischemic stroke – A review of its significance and the potential impact of therapeutic intervention by C1 esterase inhibitors, Front. Immunol. 25 (9) (2018 May) 1151.
